Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.8%. By the end of trading, Illumina rose $1.08 (1.1%) to $99.37 on light volume. Throughout the day, 706,636 shares of Illumina exchanged hands as compared to its average daily volume of 1,097,600 shares. The stock ranged in a price between $97.61-$99.69 after having opened the day at $98.93 as compared to the previous trading day's close of $98.29. Other companies within the Health Care sector that increased today were:
), up 20.6%,
), up 17.3%,
), up 15.5% and
), up 14.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $12.4 billion and is part of the drugs industry. The company has a P/E ratio of 115.7, above the S&P 500 P/E ratio of 17.7. Shares are up 76.9% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.
- You can view the full Illumina Ratings Report.
On the negative front,
), down 39.4%,
), down 21.7%,
), down 15.5% and
), down 8.6% , were all laggards within the health care sector with
) being today's health care sector laggard.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.